Company Profile

GATEKEEPER Pharmaceuticals Inc
Profile last edited on: 4/27/2018      CAGE: 5DGP1      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1170 Tuolumne Court
Millbrae, CA 94030
   (650) 307-7770
Location: Single
Congr. District: 14
County: San Mateo

Public Profile

GATEKEEPER Pharmaceuticals had focused on developing next generation small molecule drugs that overcome resistance arising from treatment by targeted oncology agents. GATEKEEPER's lead product was to be a proprietary EGFR inhibitor that potently overcomes resistance to Tarceva® and Iressa® treatment. What happened to the firm is a cautionary tale that is worth noting: Principals of the firm - serial entrepreneurs - became aware that a cancer drug candidate being developed by researchers at the Dana-Farber showed promise in treating some non-small-cell lung cancers resistant to other available drug treatments. An option agreement was established between Dana Farber and Gatekeeper principals in early 2009 by which -- if the small firm could raise initial financing -- they wouldbe granted a license. By Spring 2010, the Founder had secured that required funding; an NIH SBIR award was approved and Gatekeeper was ready to exercise its option for the patent. PROBLEM: in 2005 a major pharmaceutical firm had established a research agreement with Dana-Farber to include project grants for work that may have been related to the drug under development, That Major Corporation claimed that, under the terms of its research agreement with Dana-Farber, it had first rights to the patent that would be crucial to the small firm’s operations. Having previously determined that research funded by Large Firm did not include the now patented work, when confronted Dana Farber changed iposition. That decision caused Gatekeeper investors to withdraw their funding. A series of lawsuits followed among the three parties. Long story short - In October 2012, a US district court in Massachusetts issued a summary judgment concluding that Large Firm could not prove it was entitled to a license to the technology under the research agreement. Gatekeeper had won - but it was hollow victory. Too much time had past, critical groundwork had not been laid and though the principals have sucessfully launched other endeavors, Gateway was no more. The p

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $294,778
Project Title: Development Of Mutant Selective Egfr Kinase Inhibitors Against Egfr T790m

Key People / Management

  John S Chant -- President